Related Experiment Video
Updated: Jun 22, 2025

Measurement of Heme Synthesis Levels in Mammalian Cells
Published on: July 9, 2015
[HIF-ɑ: New Target For Treatment of Renal Anemia. Molecular Aspects and Activation of Pathway HREs]
Fabio Mazza1, Angela Cicciarelli1, Filomena Rubino1
1UO Nefrologia e Dialisi, Ospedale SS Trinità Sora, Italia.
Roxadustat, recently approved, is a hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. This article reviews main features and possible effects by activation of pathway sequences HREs.
Roxadustat, recently approved, is a hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. This article reviews main features and possible effects by activation of pathway sequences HREs.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Erythropoiesis
Targeted Cancer Therapies
There are several types of targeted therapies against...

